Omeros (NASDAQ:OMER) Coverage Initiated at D. Boral Capital

Research analysts at D. Boral Capital initiated coverage on shares of Omeros (NASDAQ:OMER) in a research note issued to investors on Monday, Marketbeat.com reports. The firm set a “buy” rating and a $36.00 price target on the biopharmaceutical company’s stock. D. Boral Capital’s target price would suggest a potential upside of 260.00% from the stock’s previous close.

A number of other equities research analysts also recently issued reports on the stock. StockNews.com raised shares of Omeros from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. Needham & Company LLC restated a “hold” rating on shares of Omeros in a research note on Thursday, December 19th. Rodman & Renshaw assumed coverage on Omeros in a research report on Thursday, November 14th. They set a “buy” rating and a $9.00 price target for the company. Cantor Fitzgerald reiterated a “neutral” rating on shares of Omeros in a report on Thursday, November 14th. Finally, RODMAN&RENSHAW upgraded Omeros to a “strong-buy” rating in a report on Thursday, November 14th. Three research analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $22.50.

Omeros Trading Down 1.1 %

Shares of OMER opened at $10.00 on Monday. The company’s 50-day moving average price is $7.21 and its 200 day moving average price is $5.24. Omeros has a 12-month low of $2.61 and a 12-month high of $13.60. The firm has a market cap of $579.50 million, a P/E ratio of -4.33 and a beta of 1.97.

Institutional Trading of Omeros

A number of large investors have recently modified their holdings of the stock. Wellington Management Group LLP purchased a new position in Omeros in the third quarter valued at $305,000. Barclays PLC raised its position in Omeros by 121.3% in the 3rd quarter. Barclays PLC now owns 94,640 shares of the biopharmaceutical company’s stock valued at $376,000 after purchasing an additional 51,873 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Omeros by 16.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 218,580 shares of the biopharmaceutical company’s stock valued at $887,000 after buying an additional 31,081 shares during the period. AQR Capital Management LLC acquired a new position in shares of Omeros during the second quarter worth about $105,000. Finally, SG Americas Securities LLC purchased a new stake in shares of Omeros during the third quarter worth approximately $80,000. Hedge funds and other institutional investors own 48.79% of the company’s stock.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.